All In Biotech

Drug Trial Radar · NCT03155620

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

1,377

Actual

Start

Jul 31, 2017

Primary completion

Mar 31, 2025

Study completion Jan 6, 2027

Sponsor

Sponsor type
NIH
First posted
May 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Ann Arbor Stage III Non-Hodgkin Lymphoma
  • Ann Arbor Stage IV Non-Hodgkin Lymphoma
  • Histiocytic Sarcoma
  • Juvenile Xanthogranuloma
  • Langerhans Cell Histiocytosis
  • Malignant Glioma
  • Recurrent Childhood Rhabdomyosarcoma
  • Recurrent Ependymoma
  • Recurrent Ewing Sarcoma
  • Recurrent Glioma
  • Recurrent Hepatoblastoma
  • Recurrent Langerhans Cell Histiocytosis
  • Recurrent Malignant Germ Cell Tumor
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Medulloblastoma
  • Recurrent Neuroblastoma
  • Recurrent Non-Hodgkin Lymphoma
  • Recurrent Osteosarcoma
  • Recurrent Peripheral Primitive Neuroectodermal Tumor
  • Recurrent Primary Central Nervous System Neoplasm
  • Recurrent Rhabdoid Tumor
  • Recurrent Soft Tissue Sarcoma
  • Refractory Ewing Sarcoma
  • Refractory Glioma
  • Refractory Hepatoblastoma
  • Refractory Langerhans Cell Histiocytosis
  • Refractory Malignant Germ Cell Tumor
  • Refractory Malignant Solid Neoplasm
  • Refractory Medulloblastoma
  • Refractory Neuroblastoma
  • Refractory Non-Hodgkin Lymphoma
  • Refractory Osteosarcoma
  • Refractory Peripheral Primitive Neuroectodermal Tumor
  • Refractory Primary Central Nervous System Neoplasm
  • Refractory Rhabdoid Tumor
  • Refractory Rhabdomyosarcoma
  • Rhabdoid Tumor
  • Stage III Osteosarcoma AJCC v7
  • Stage III Soft Tissue Sarcoma AJCC v7
  • Stage IV Osteosarcoma AJCC v7
  • Stage IV Soft Tissue Sarcoma AJCC v7
  • Stage IVA Osteosarcoma AJCC v7
  • Stage IVB Osteosarcoma AJCC v7
  • Wilms Tumor

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow Aspiration and BiopsyProcedure

    Undergo a bone marrow and/or biopsy

  • Bone ScanProcedure

    Undergo a bone scan

  • Computed TomographyProcedure

    Undergo CT, PET/Ct, and/or CT/MRI

  • EnsartinibDrug

    Given PO

  • ErdafitinibDrug

    Given PO

  • IvosidenibDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Undergo molecular analysis

  • Larotrectinib SulfateDrug

    Given PO or via nasogastric- or gastric-tube

  • Magnetic Resonance ImagingProcedure

    Undergo MRI, PET/MRI, and/or CT/MRI

  • Mutation Carrier ScreeningProcedure

    Undergo tumor tissue mutation screening

  • OlaparibDrug

    Given PO

  • PalbociclibDrug

    Given PO

  • Pharmacological StudyOther

    Correlative studies

  • Positron Emission TomographyProcedure

    Undergo PET, PET/CT, and/or PET/MRI

  • Radionuclide ImagingProcedure

    Undergo radionuclide imaging

  • SamotolisibDrug

    Given PO

  • SelpercatinibDrug

    Given PO

  • Selumetinib SulfateDrug

    Given PO

  • TazemetostatDrug

    Given PO

  • TipifarnibDrug

    Given PO or via nasogastric or gastric tube

  • UlixertinibDrug

    Receive PO

  • VemurafenibDrug

    Given PO

  • X-Ray ImagingProcedure

    Undergo an x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer DrugsTime frame: Up to 2 years from study entry

Locations

172 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Banner Children's at Desert

    Mesa, Arizona

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Mattel Children's Hospital UCLA

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • Naval Medical Center -San Diego

    San Diego, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • Arnold Palmer Hospital for Children

    Orlando, Florida

  • Nemours Children's Hospital

    Orlando, Florida

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.